

Francesco P Russo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9157691/publications.pdf>

Version: 2024-02-01

183
papers

5,320
citations

87888

38
h-index

106344

65
g-index

202
all docs

202
docs citations

202
times ranked

6857
citing authors

#	ARTICLE	IF	CITATIONS
1	Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5060-5065.	7.1	539
2	The Bone Marrow Functionally Contributes to Liver Fibrosis. Gastroenterology, 2006, 130, 1807-1821.	1.3	467
3	A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology, 2004, 126, 955-963.	1.3	405
4	Hepatic stem cells: from inside and outside the liver?. Cell Proliferation, 2004, 37, 1-21.	5.3	145
5	Adherence in liver transplant recipients. Liver Transplantation, 2011, 17, 760-770.	2.4	138
6	The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. Hepatology, 2006, 43, 316-324.	7.3	132
7	Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. Journal of Hepatology, 2018, 69, 345-352.	3.7	128
8	Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. Journal of Hepatology, 2013, 58, 287-296.	3.7	99
9	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology, 2019, 156, 96-107.e1.	1.3	82
10	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2019, 51, 190-205.	0.9	77
11	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Journal of Hepatology, 2019, 71, 1106-1115.	3.7	69
12	Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Annals of Surgical Oncology, 2010, 17, 2290-2302.	1.5	66
13	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut, 2022, 71, 593-604.	12.1	62
14	When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Digestive and Liver Disease, 2018, 50, 640-646.	0.9	59
15	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology, 2022, 76, 812-821.	3.7	59
16	Apoptotic Effects of Selected Strains of Lactic Acid Bacteria on a Human T Leukemia Cell Line Are Associated With Bacterial Arginine Deiminase and/or Sphingomyelinase Activities. Nutrition and Cancer, 2001, 40, 185-196.	2.0	58
17	Systemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury. BMC Gastroenterology, 2012, 12, 88.	2.0	58
18	Markers of acute rejection and graft acceptance in liver transplantation. World Journal of Gastroenterology, 2015, 21, 1061.	3.3	57

#	ARTICLE	IF	CITATIONS
19	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.	0.9	53
20	Homologous acellular matrix (HAM): a new support for hepatocyte culture. <i>Journal of Hepatology</i> , 2002, 36, 218-219.	3.7	51
21	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	3.7	51
22	Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 821-829.	2.0	49
23	Umbilical cord mesenchymal stem cells modulate dextran sulfate sodium induced acute colitis in immunodeficient mice. <i>Stem Cell Research and Therapy</i> , 2015, 6, 79.	5.5	49
24	Expression of Matrix Metalloproteinases and Their Specific Inhibitors in Normal and Different Human Thyroid Tumor Cell Lines. <i>Thyroid</i> , 2004, 14, 881-888.	4.5	48
25	Sexual Dysfunction in Chronic Liver Disease: Is Liver Transplantation an Effective Cure?. <i>Transplantation</i> , 2010, 89, 1425-1429.	1.0	48
26	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	3.7	47
27	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017, 23, 1103-1112.	2.4	46
28	Heparanase and macrophage interplay in the onset of liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 14956.	3.3	46
29	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. <i>Transplantation</i> , 2012, 94, 784-793.	1.0	45
30	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	7.3	45
31	Stem and progenitor cells in liver regeneration and repair. <i>Cytotherapy</i> , 2011, 13, 135-144.	0.7	44
32	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	3.7	44
33	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	3.7	43
34	The survival benefit of liver transplantation in hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2010, 42, 642-649.	0.9	42
35	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	2.5	42
36	Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins. <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 71-75.	1.4	41

#	ARTICLE	IF	CITATIONS
37	Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transplantation, 2009, 15, 619-628.	2.4	41
38	Risk Factors for Central Pontine and Extrapontine Myelinolysis After Liver Transplantation. Transplantation, 2015, 99, 1257-1264.	1.0	40
39	Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver International, 2018, 38, 2210-2218.	3.9	39
40	Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clinical Rheumatology, 2019, 38, 2843-2850.	2.2	39
41	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2020, 18, 1188-1196.e3.	4.4	39
42	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Journal of Hepatology, 2020, 73, 593-602.	3.7	38
43	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.	2.5	37
44	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. International Journal of Molecular Sciences, 2022, 23, 500.	4.1	37
45	Understanding of and attitudes to xenotransplantation: a survey among Italian university students. Xenotransplantation, 2004, 11, 133-140.	2.8	36
46	Prevalence of celiac disease in adult patients with refractory functional dyspepsia: Value of routine duodenal biopsy. World Journal of Gastroenterology, 2008, 14, 6948.	3.3	36
47	Liver transplantation for viral hepatitis in 2015. World Journal of Gastroenterology, 2016, 22, 1570.	3.3	36
48	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. Acta Dermato-Venereologica, 2012, 92, 411-415.	1.3	34
49	Stem cells in liver failure. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 35-45.	2.4	34
50	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. Liver International, 2018, 38, 2190-2198.	3.9	33
51	Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. World Journal of Gastroenterology, 2018, 24, 4403-4411.	3.3	31
52	Liver histopathology in COVID-19 patients: A mono-Institutional series of liver biopsies and autopsy specimens. Pathology Research and Practice, 2021, 221, 153451.	2.3	30
53	Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis. Nutrients, 2019, 11, 1602.	4.1	29
54	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Liver International, 2021, 41, 2455-2466.	3.9	29

#	ARTICLE	IF	CITATIONS
55	Risk Factors in Liver Replantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2011, 43, 1110-1113.	0.6	28
56	Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 829-845.	6.7	28
57	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1853-1859.	2.4	27
58	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , 2019, 11, 1568.	3.7	27
59	Invasive fungal infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 7485-7496.	3.3	26
60	Modeling cost-effectiveness and health gains of a universal versus prioritized hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	7.3	25
61	Iodine supplementation restores fertility of sheep exposed to iodine deficiency. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 1081-1087.	3.3	24
62	The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1878-1885.	0.4	24
63	Hepatitis C virus infection in end-stage renal disease and kidney transplantation. <i>Transplant International</i> , 2014, 27, 877-891.	1.6	23
64	Common issues in the management of patients in the waiting list and after liver transplantation. <i>Digestive and Liver Disease</i> , 2017, 49, 241-253.	0.9	23
65	Organ Preservation in Liver Transplantation. <i>Seminars in Liver Disease</i> , 2018, 38, 260-269.	3.6	23
66	The Extra Virgin Olive Oil Polyphenol Oleocanthal Exerts Antifibrotic Effects in the Liver. <i>Frontiers in Nutrition</i> , 2021, 8, 715183.	3.7	23
67	Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). <i>Journal of Hepatology</i> , 2022, 76, 364-370.	3.7	22
68	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1168-1176.	2.0	21
69	Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury. <i>Clinical Science</i> , 2018, 132, 255-272.	4.3	21
70	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	3.7	21
71	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. <i>Cancers</i> , 2021, 13, 2274.	3.7	21
72	Recent advances in understanding and managing liver transplantation. <i>F1000Research</i> , 2016, 5, 2895.	1.6	21

#	ARTICLE	IF	CITATIONS
73	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	2.0	20
74	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. <i>Digestive and Liver Disease</i> , 2022, 54, 237-242.	0.9	20
75	New Indications for Liver Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3867.	2.4	20
76	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.9	19
77	New Perspectives in Liver Transplantation: From Regeneration to Bioengineering. <i>Bioengineering</i> , 2019, 6, 81.	3.5	19
78	Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis. <i>JHEP Reports</i> , 2021, 3, 100286.	4.9	19
79	COVID-19 and liver disease: where are we now?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 277-278.	17.8	19
80	Estimation of the Harm to the Waiting List as a Crucial Factor in the Selection of Patients With Hepatocellular Carcinoma for Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1194-1196.	0.6	18
81	Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome. <i>Transplantation</i> , 2013, 95, 1528-1534.	1.0	17
82	Therapeutic application of stem cells in gastroenterology: An up-date. <i>World Journal of Gastroenterology</i> , 2011, 17, 3870.	3.3	17
83	Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 1097.	2.0	17
84	Acellular liver matrix improves the survival and functions of isolated rat hepatocytes cultured in vitro. <i>International Journal of Molecular Medicine</i> , 2004, 14, 511-5.	4.0	17
85	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	4.3	16
86	The Nuclear Receptor PXR in Chronic Liver Disease. <i>Cells</i> , 2022, 11, 61.	4.1	16
87	Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8874.	4.1	15
88	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021, 13, 4882.	3.7	15
89	Donor-Model for End-Stage Liver Disease and Donor-Recipient Matching in Liver Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 974-976.	0.6	14
90	Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. <i>World Journal of Gastroenterology</i> , 2017, 23, 2095.	3.3	14

#	ARTICLE	IF	CITATIONS
91	Management of bacterial infection in the liver transplant candidate. <i>World Journal of Hepatology</i> , 2018, 10, 222-230.	2.0	14
92	Functional and morphological graft monitoring after liver transplantation. <i>Clinica Chimica Acta</i> , 2001, 310, 17-23.	1.1	13
93	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021, 41, 2228-2232.	3.9	13
94	Induction of Apoptosis by 1,4-Benzothiazine Analogs in Mouse Thymocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 1053-1062.	2.5	12
95	Hepatitis C virus and liver transplantation: where do we stand?. <i>Transplant International</i> , 2016, 29, 135-152.	1.6	12
96	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. <i>Pharmacoeconomics</i> , 2019, 37, 255-266.	3.3	12
97	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	3.9	12
98	Recent Advances in the Management of Acute Variceal Hemorrhage. <i>Journal of Clinical Medicine</i> , 2021, 10, 3818.	2.4	12
99	Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 775-782.	2.3	12
100	Inflammatory Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 959-974.	1.2	12
101	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	7.3	12
102	Prognostic Evaluation of the Donor Risk Index Among a Prospective Cohort of Italian Patients Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1096-1098.	0.6	11
103	Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 858-864.	2.0	11
104	Fibrosis Progression and the Pros and Cons of Antiviral Therapy for Hepatitis C Virus Recurrence After Liver Transplantation: A Review. <i>Transplantation Proceedings</i> , 2010, 42, 2223-2225.	0.6	10
105	Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. <i>Liver International</i> , 2018, 38, 1770-1776.	3.9	10
106	Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. <i>Journal of Clinical Medicine</i> , 2020, 9, 1353.	2.4	10
107	Experimental hepatology applied to stem cells. <i>Digestive and Liver Disease</i> , 2008, 40, 54-61.	0.9	9
108	Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000183.	2.7	9

#	ARTICLE	IF	CITATIONS
109	Short-term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service. <i>Liver International</i> , 2018, 38, 1316-1321.	3.9	9
110	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	3.7	9
111	Natural \pm -IFN in HCV recurrence after liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1457-1458.	0.6	8
112	Use of Grafts From Anti-HBc-Positive Donors in Liver Transplantation: A 5-Year, Single-Center Experience. <i>Transplantation Proceedings</i> , 2013, 45, 2707-2710.	0.6	8
113	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	4.2	8
114	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , 2015, 28, 1055-1065.	1.6	7
115	Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
116	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
117	A prospective longitudinal assessment of <i>de novo</i> metabolic syndrome after liver transplantation. <i>Clinical Transplantation</i> , 2022, 36, e14532.	1.6	7
118	A challenging liver transplantation for decompensated alcoholic liver disease after recovery from SARS-CoV-2 infection. <i>Transplant International</i> , 2021, 34, 756-757.	1.6	6
119	Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy. <i>Medicina (Lithuania)</i> , 2022, 58, 290.	2.0	6
120	Physiological and clinical implications of proANP(1-98) circulating levels in the perioperative phase of liver transplantation. <i>Clinica Chimica Acta</i> , 2001, 310, 39-48.	1.1	5
121	HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A true-or-false game. <i>Digestive and Liver Disease</i> , 2017, 49, 321-325.	0.9	5
122	Hemodynamic Evaluation of Nonselective β -Blockers in Patients with Cirrhosis and Refractory Ascites. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	5
123	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1187-1197.	2.4	5
124	Hepatic benefits of HCV cure: Don't forget coagulation!. <i>Journal of Hepatology</i> , 2021, 74, 967-968.	3.7	5
125	Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis. <i>Internal and Emergency Medicine</i> , 2021, 16, 349-357.	2.0	5
126	New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation. <i>Annals of Transplantation</i> , 2016, 21, 632-643.	0.9	5

#	ARTICLE	IF	CITATIONS
127	Transfusion-associated circulatory overload in gastroenterology. <i>Blood Transfusion</i> , 2021, 19, 197-204.	0.4	5
128	Algorithm for Prioritization of Patients on the Waiting List for Liver Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 1855-1856.	0.6	4
129	HCV Histological Recurrence and Survival Following Liver Transplantation in Patients With and Without Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2008, 40, 1974-1975.	0.6	4
130	Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. <i>Transplant International</i> , 2016, 29, 694-697.	1.6	4
131	GS-18-Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival. <i>Journal of Hepatology</i> , 2019, 70, e84.	3.7	4
132	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
133	HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist. <i>Journal of Hepatology</i> , 2022, , .	3.7	4
134	<scp>Sarsâ€Cov</scp>â€2 vaccination in liver transplant recipients: The "holy grail"™ in a hostile environment. <i>Liver International</i> , 2022, 42, 1225-1228.	3.9	4
135	Bone marrow cells in the liver: Diverse cells, diverse effects. <i>Hepatology</i> , 2007, 46, 604-605.	7.3	3
136	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.	1.6	3
137	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	3
138	Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 482-483.	3.7	3
139	Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 253-259.	0.8	3
140	Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 376-377.	0.8	3
141	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, 26-37.	0.5	3
142	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, 4-10.	0.5	3
143	Study of the microcirculation in hDAF transgenic rat livers xenoperfused with human blood. <i>Xenotransplantation</i> , 2009, 16, 83-90.	2.8	2
144	Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , 2011, 6, 1179-1186.	1.8	2

#	ARTICLE	IF	CITATIONS
145	COVID-19 in Padua, Italy: not just an economic and health issue. <i>Nature Medicine</i> , 2020, 26, 806-806.	30.7	2
146	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.9	2
147	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. <i>Antiviral Therapy</i> , 2020, 25, 73-81.	1.0	2
148	Hepatitis B and liver transplantation. <i>Minerva Gastroenterology</i> , 2018, 64, 147-157.	0.5	2
149	GH/GHBP changes in the perioperative course of liver transplantation: pathophysiologic and clinical implications. <i>Transplantation Proceedings</i> , 2001, 33, 1390-1392.	0.6	1
150	Histological features of donor grafts for orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1177-1178.	0.6	1
151	THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. <i>Journal of Hepatology</i> , 2019, 70, e234-e235.	3.7	1
152	Young GI angle: A young point of view on translational medicine. <i>United European Gastroenterology Journal</i> , 2019, 7, 864-865.	3.8	1
153	THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients. <i>Journal of Hepatology</i> , 2019, 70, e223-e224.	3.7	1
154	Role of a dedicated referral system for patients with liver disease and potential indication for liver transplantation: prospective data from a single centre experience. <i>Digestive and Liver Disease</i> , 2020, 52, e70-e71.	0.9	1
155	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	1.6	1
156	Drug induced liver injury: from pathogenesis to liver transplantation. <i>Minerva Gastroenterology</i> , 2021, 67, 50-64.	0.5	1
157	The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. <i>Biology</i> , 2022, 11, 693.	2.8	1
158	The role of the steatosis of the donor graft on histological features after liver transplantation (LT). <i>Gastroenterology</i> , 2003, 124, A691.	1.3	0
159	New insight in the biologic support of rat hepatocytes in primary culture. <i>Gastroenterology</i> , 2003, 124, A123.	1.3	0
160	HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience. <i>Digestive and Liver Disease</i> , 2016, 48, e237.	0.9	0
161	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e37.	0.9	0
162	Coronary microvascular dysfunction in patients with decompensated cirrhosis: Another tool for understanding cirrhotic cardiomyopathy?. <i>Digestive and Liver Disease</i> , 2016, 48, e59.	0.9	0

#	ARTICLE	IF	CITATIONS
163	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. <i>Digestive and Liver Disease</i> , 2017, 49, e9.	0.9	0
164	Outcome of liver transplant recipients after the first episode of bacterial infection. <i>Digestive and Liver Disease</i> , 2017, 49, e12.	0.9	0
165	Evolution of liver transplantation for alcoholic liver disease: A single center study. <i>Digestive and Liver Disease</i> , 2017, 49, e240.	0.9	0
166	Reply. <i>Liver Transplantation</i> , 2017, 23, 1630-1631.	2.4	0
167	The Efficacy of CMV Specific Immune Reconstitution is Highly Dependent on Donor/Recipient Serostatus and Type of Solid Organ Transplanted. <i>Transplantation</i> , 2018, 102, S334.	1.0	0
168	PS-185-Magnetic resonance risk score and liver stiffness by transient elastography have complementary prognostic values in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e114.	3.7	0
169	THU-071-Matrix modulation in chronic liver injury and resolution. <i>Journal of Hepatology</i> , 2019, 70, e190.	3.7	0
170	THU-304-Modeling NAFLD-related disease progression among the PITER SVR12 cohort. <i>Journal of Hepatology</i> , 2019, 70, e294.	3.7	0
171	THU-444-Alteration of miRNAs expression in patients with HCV-related cirrhosis who developed HCC after therapy with DAAs. <i>Journal of Hepatology</i> , 2019, 70, e354.	3.7	0
172	The role of delta creatinine and serum albumin in predicting mortality in patients with severe alcoholic hepatitis and infection. <i>Digestive and Liver Disease</i> , 2019, 51, e29.	0.9	0
173	The role of alcoholic liver disease as risk factor for the development of de novo metabolic syndrome after liver transplantation: a prospective longitudinal study. <i>Digestive and Liver Disease</i> , 2019, 51, e51.	0.9	0
174	The administration of a high-fat diet alters bile acid composition and hepatic drug metabolism in rats. <i>Digestive and Liver Disease</i> , 2019, 51, e22.	0.9	0
175	De novo neoplasms after liver transplantation: donor gender and age influence. <i>Digestive and Liver Disease</i> , 2019, 51, e50.	0.9	0
176	Long-term liver function changes and related risk factors after direct-acting antiviral therapy in HCV-infected cirrhotic patients: results from a prospective web-based regional platform. <i>Digestive and Liver Disease</i> , 2019, 51, e16.	0.9	0
177	450 CLONAL DYNAMICS AND CELL-OF-ORIGIN OF NORMAL HEPATOCYTE EXPANSIONS IN HOMEOSTATIC HUMAN LIVERS AND THEIR ASSOCIATION WITH THE BILIARY EPITHELIUM. <i>Gastroenterology</i> , 2020, 158, S-1276.	1.3	0
178	Long-term liver fibrosis and outcomes in HCV-infected solid organ transplant recipients after DAAs-induced viral eradication. <i>Digestive and Liver Disease</i> , 2020, 52, e22.	0.9	0
179	<i>Transplant and Autoimmune Diseases</i> , , 2021, , 281-293.		0
180	Therapeutic approaches for the treatment of aging-induced stem cell dysfunction. , 2021, , 223-230.		0

#	ARTICLE	IF	CITATIONS
181	Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study. Digestive and Liver Disease, 2021, , .	0.9	0
182	Adult Liver Stem Cells. Pancreatic Islet Biology, 2014, , 319-338.	0.3	0
183	Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy. Minerva Gastroenterology, 2021, 67, 38-49.	0.5	0